Compare Kroger Co (KR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Repligen Corporation Common Stock — how do they compare? Kroger Co trades at $63 (market cap $35.87B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Kroger Co is far larger — about 3.2× Repligen Corporation Common Stock's market cap, and Kroger Co pays a 2.57% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 109 Days and Repligen Corporation Common Stock for 0 Days on average.
| KR | RGEN | |
|---|---|---|
Market Cap | $35.87B | $11.14B |
Volume | 8,902,665 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $194.57 |
52-Week Low | $55.53 | $102.87 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $57.29B | $11.02B |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $63.09, up 0.85% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a low P/S of 0.26 and positive cash flow trends, though net income margin is thin at 0.73%. Recent news highlights digital growth and a strategic shift toward everyday low prices, while earnings have mostly beaten expectations.
Outlook is cautiously optimistic with a $70.62 consensus price target, but risks include integration challenges from acquisitions and cost pressures. The stock offers value with a dividend yield, yet investors should weigh slower sales guidance against operational improvements for near-term performance.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
